Every 10-Q that Aspira Womens Health Inc (AWHL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AWHL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AWHL filings page.
Aspira Women’s Health Inc. reported continued operating losses and liquidity pressure for the quarter ended June 30, 2026. Q2 revenue was $2.046 million, down from $2.404 million a year earlier, with a gross profit of $1.131 million. Total operating expenses were $2.966 million, leading to a loss from operations of $1.835 million.
Including a $0.485 million loss from remeasuring warrant liabilities and net interest expense, Q2 net loss was $2.420 million (basic and diluted loss per share $0.05). For the first six months of 2026, revenue fell to $4.013 million from $4.683 million, but net loss narrowed to $1.744 million from $4.519 million, helped by a $2.625 million non‑cash gain from warrant revaluation.
Cash and cash equivalents declined to $0.477 million at June 30, 2026, with net cash used in operating activities of $2.369 million in the first half. Management disclosed a working capital deficit of about $2.542 million and an accumulated deficit of about $545.9 million, concluding there is substantial doubt about the company’s ability to continue as a going concern within one year. To support liquidity, Aspira completed a $1.41 million June 2026 private placement, utilized its Lincoln Park equity line, and relies on OvaSuite product sales as its primary recurring cash source.
Aspira Women’s Health Inc. reported Q1 2026 results showing fragile finances despite an accounting profit. Revenue from its OvaSuite diagnostic tests was $1.967M, down from $2.279M a year earlier, and the company recorded a loss from operations of $2.203M.
Net income was $0.676M, driven mainly by a non‑cash $3.11M gain from revaluing warrant liabilities, along with higher interest expense. Cash and cash equivalents were only $1.344M against total liabilities of $11.295M and a working capital deficit of about $1.81M, leading management to state there is “substantial doubt” about its ability to continue as a going concern.
The company was delisted from Nasdaq in 2025 and now trades on the OTC QX Market. To fund operations, it relies on high‑cost debt, including a subordinated loan with a 42% interest rate, and equity facilities such as a $10M purchase agreement with Lincoln Park, of which $7k was used in Q1.
Aspira Women’s Health Inc. reported Q3 2025 results. Revenue was $2,305,000, with gross profit of $1,383,000. Operating expenses were $2,962,000, leading to a loss from operations of $1,579,000. A non-cash loss from the change in fair value of warrant liabilities of $4,309,000 drove total other (expense) income, net to $(3,313,000), and the company recorded a net loss of $4,892,000 for the quarter.
For the nine months ended September 30, 2025, revenue was $6,988,000 and net loss was $9,411,000. Cash and cash equivalents were $3,809,000, working capital was $1,626,000, and long-term debt (DECD loan) was $1,100,000. Warrant liabilities increased to $5,280,000, largely tied to March 2025 warrants measured at fair value. Financing during 2025 included $3,484,000 in gross proceeds under the 2024 at-the-market program and $2,949,000 in gross proceeds from a September 2025 private placement.
The company disclosed substantial doubt about its ability to continue as a going concern within one year. Its common stock was delisted from Nasdaq in April 2025 and began trading on the OTC QX Best Market on October 14, 2025.